Skip to main content

Find a clinical trial


A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile associated diarrhea (CDAD) Mickael Aoun


A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Philippe Aftimos

CA209358 / CheckMate 358

Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors. Ahmad Hussein Awada


CA209-142 A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer Alain Hendlisz


An open label, Phase Ia/Ib dose finding study with BI 894999 orally administeredonce a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Ahmad Hussein Awada


An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors Christiane Jungels


CIRSE Registry for SIR-Spheres Therapy (CIRT) Patrick Flamen


An open-label dose escalation Phase I study to assess the safety and clinical activity of multiple hepatic transarterial administrations of NKR-2 in patients with unresectable liver metastases from colorectal cancer Alain Hendlisz


An open-label, Phase I study to assess the safety and clinical activity of multiple doses of NKR-2, administered concurrently with the neoadjuvant Folfox treatment in patients with potentially resectable liver metastases from colorectal cancer Alain Hendlisz


a phase 2, multicenter, randomized, double-blind study of the safety, tolerability and efficacy of intravenous CD101 vs intravenous caspofungin followed by oral fluconazole stept-down in the treatment of subjects with candidemia Mickael Aoun

EORTC 1658

Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Konstantinos Stathopoulos


A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respiratory Syncytial Virus (RSV) Infection Mickael Aoun

Intervention dyadique

Reinforcement of onco-psychological interventions by the development of psychological support for patients and their significant others


A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies


A Phase 1/2, Open-Label, Dose-Escalation / Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies Ahmad Hussein Awada

INCB 01158-203

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors. (INCB01158-203)


A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy


A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Philippe Aftimos


CHRONOS & KAIROS Project : Creation of a Prospective Combined Clinical and Biological Database to Capture in Parallel the Patient's Clinical History AND Tumoral Qualitative and Quantitative Changes During the Course of the Disease Alain Hendlisz


Assessment of Metabolic and pathological Response to Treatment with Radio-chemotherapy (RCT) and Immunotherapy before Surgery in locally advanced Esophageal and gastro-esophageal junction cancer: ARTemIS-Eso phase I study Amelie Deleporte

Follow us!

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more